These findings collectively indicate that cuproptosis-mediated upregulation of PD-L1 expression significantly enhances tumor sensitivity to αPD-L1 antibody therapy, providing robust evidence to support the potential clinical application of combining cuproptosis induction with immune checkpoint blockade strategies. This evidence concerns the gene CD274 and neoplasm.